Mustang Operating Income vs Reconciled Depreciation Analysis

MBIO Stock

USD 0.22 0.01 4.76%

Mustang Bio financial indicator trend analysis is infinitely more than just investigating Mustang Bio recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Mustang Bio is a good investment. Please check the relationship between Mustang Bio Operating Income and its Reconciled Depreciation accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mustang Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Mustang Stock, please use our How to Invest in Mustang Bio guide.

Operating Income vs Reconciled Depreciation

Operating Income vs Reconciled Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Mustang Bio Operating Income account and Reconciled Depreciation. At this time, the significance of the direction appears to have pay attention.

The correlation between Mustang Bio's Operating Income and Reconciled Depreciation is -0.92. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Reconciled Depreciation in the same time period over historical financial statements of Mustang Bio, assuming nothing else is changed. The correlation between historical values of Mustang Bio's Operating Income and Reconciled Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of Mustang Bio are associated (or correlated) with its Reconciled Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Reconciled Depreciation has no effect on the direction of Operating Income i.e., Mustang Bio's Operating Income and Reconciled Depreciation go up and down completely randomly.

Correlation Coefficient

-0.92

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Operating Income

Operating Income is the amount of profit realized from Mustang Bio operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Mustang Bio is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Reconciled Depreciation

Most indicators from Mustang Bio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Mustang Bio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mustang Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Mustang Stock, please use our How to Invest in Mustang Bio guide.As of the 18th of October 2024, Selling General Administrative is likely to drop to about 9 M. In addition to that, Issuance Of Capital Stock is likely to drop to about 155.8 K

Mustang Bio fundamental ratios Correlations

	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Stockholder Equity	Total Liab	Short Long Term Debt	Short Term Debt	Common Stock	Total Assets	Current Deferred Revenue	Cash	Cash And Short Term Investments	Retained Earnings Total Equity	Total Current Assets	Other Liab	Property Plant And Equipment Net	Net Receivables
Short Long Term Debt Total		-0.3	0.34	0.25	0.23	-0.16	-0.23	0.5	0.18	-0.33	0.79	0.23	0.33	0.72	-0.3	-0.22	0.56	0.37	-0.37	0.22	0.32	-0.29	0.33	0.34	0.44	-0.24
Other Current Liab	-0.3		0.47	0.09	0.61	-0.17	-0.6	0.27	0.67	-0.24	-0.17	0.66	0.47	0.17	-0.4	-0.49	-0.06	-0.01	-0.19	-0.04	-0.1	-0.57	-0.06	0.3	0.31	0.71
Total Current Liabilities	0.34	0.47		0.36	0.86	-0.43	-0.93	0.84	0.88	-0.14	0.51	0.88	0.95	0.82	-0.51	-0.66	0.61	0.44	0.03	0.37	0.31	-0.9	0.36	0.47	0.77	0.49
Total Stockholder Equity	0.25	0.09	0.36		0.53	-0.98	-0.32	0.67	0.5	-0.65	0.11	0.53	0.6	0.29	-0.62	-0.67	0.81	0.95	-0.56	0.87	0.93	-0.63	0.94	0.33	0.69	-0.29
Net Tangible Assets	0.23	0.61	0.86	0.53		-0.56	-0.96	0.86	0.99	-0.47	0.23	0.99	0.94	0.64	-0.74	-0.86	0.56	0.48	-0.16	0.35	0.35	-0.94	0.41	0.53	0.79	0.6
Net Debt	-0.16	-0.17	-0.43	-0.98	-0.56		0.39	-0.69	-0.56	0.57	-0.14	-0.58	-0.65	-0.34	0.6	0.69	-0.83	-0.95	0.43	-0.91	-0.93	0.69	-0.94	-0.27	-0.72	0.24
Retained Earnings	-0.23	-0.6	-0.93	-0.32	-0.96	0.39		-0.82	-0.97	0.26	-0.34	-0.96	-0.93	-0.73	0.6	0.74	-0.49	-0.33	-0.02	-0.23	-0.19	0.91	-0.25	-0.52	-0.77	-0.69
Accounts Payable	0.5	0.27	0.84	0.67	0.86	-0.69	-0.82		0.85	-0.41	0.49	0.86	0.92	0.78	-0.64	-0.77	0.86	0.72	-0.19	0.6	0.62	-0.91	0.66	0.56	0.89	0.19
Common Stock Total Equity	0.18	0.67	0.88	0.5	0.99	-0.56	-0.97	0.85		-0.41	0.24	1.0	0.95	0.65	-0.7	-0.83	0.56	0.47	-0.14	0.37	0.35	-0.96	0.4	0.55	0.82	0.61
Common Stock Shares Outstanding	-0.33	-0.24	-0.14	-0.65	-0.47	0.57	0.26	-0.41	-0.41		0.01	-0.44	-0.38	-0.18	0.88	0.77	-0.38	-0.44	0.73	-0.27	-0.4	0.41	-0.41	-0.52	-0.45	0.01
Non Current Liabilities Total	0.79	-0.17	0.51	0.11	0.23	-0.14	-0.34	0.49	0.24	0.01		0.26	0.38	0.89	-0.13	-0.16	0.61	0.34	0.06	0.35	0.29	-0.36	0.3	0.07	0.5	-0.16
Capital Surpluse	0.23	0.66	0.88	0.53	0.99	-0.58	-0.96	0.86	1.0	-0.44	0.26		0.95	0.67	-0.71	-0.84	0.57	0.5	-0.2	0.39	0.37	-0.97	0.42	0.58	0.84	0.58
Other Stockholder Equity	0.33	0.47	0.95	0.6	0.94	-0.65	-0.93	0.92	0.95	-0.38	0.38	0.95		0.74	-0.7	-0.83	0.71	0.61	-0.15	0.51	0.5	-0.97	0.54	0.53	0.85	0.42
Total Liab	0.72	0.17	0.82	0.29	0.64	-0.34	-0.73	0.78	0.65	-0.18	0.89	0.67	0.74		-0.43	-0.51	0.71	0.45	-0.01	0.4	0.35	-0.73	0.38	0.35	0.76	0.18
Short Long Term Debt	-0.3	-0.4	-0.51	-0.62	-0.74	0.6	0.6	-0.64	-0.7	0.88	-0.13	-0.71	-0.7	-0.43		0.96	-0.5	-0.45	0.45	-0.29	-0.37	0.66	-0.4	-0.54	-0.61	-0.26
Short Term Debt	-0.22	-0.49	-0.66	-0.67	-0.86	0.69	0.74	-0.77	-0.83	0.77	-0.16	-0.84	-0.83	-0.51	0.96		-0.6	-0.54	0.33	-0.42	-0.45	0.8	-0.49	-0.53	-0.71	-0.33
Common Stock	0.56	-0.06	0.61	0.81	0.56	-0.83	-0.49	0.86	0.56	-0.38	0.61	0.57	0.71	0.71	-0.5	-0.6		0.91	-0.23	0.87	0.87	-0.71	0.89	0.31	0.82	-0.29
Total Assets	0.37	-0.01	0.44	0.95	0.48	-0.95	-0.33	0.72	0.47	-0.44	0.34	0.5	0.61	0.45	-0.45	-0.54	0.91		-0.43	0.96	0.99	-0.65	0.99	0.23	0.74	-0.38
Current Deferred Revenue	-0.37	-0.19	0.03	-0.56	-0.16	0.43	-0.02	-0.19	-0.14	0.73	0.06	-0.2	-0.15	-0.01	0.45	0.33	-0.23	-0.43		-0.26	-0.42	0.24	-0.42	-0.46	-0.26	0.24
Cash	0.22	-0.04	0.37	0.87	0.35	-0.91	-0.23	0.6	0.37	-0.27	0.35	0.39	0.51	0.4	-0.29	-0.42	0.87	0.96	-0.26		0.97	-0.56	0.97	0.05	0.66	-0.45
Cash And Short Term Investments	0.32	-0.1	0.31	0.93	0.35	-0.93	-0.19	0.62	0.35	-0.4	0.29	0.37	0.5	0.35	-0.37	-0.45	0.87	0.99	-0.42	0.97		-0.53	1.0	0.12	0.63	-0.5
Retained Earnings Total Equity	-0.29	-0.57	-0.9	-0.63	-0.94	0.69	0.91	-0.91	-0.96	0.41	-0.36	-0.97	-0.97	-0.73	0.66	0.8	-0.71	-0.65	0.24	-0.56	-0.53		-0.58	-0.58	-0.92	-0.41
Total Current Assets	0.33	-0.06	0.36	0.94	0.41	-0.94	-0.25	0.66	0.4	-0.41	0.3	0.42	0.54	0.38	-0.4	-0.49	0.89	0.99	-0.42	0.97	1.0	-0.58		0.16	0.67	-0.45
Other Liab	0.34	0.3	0.47	0.33	0.53	-0.27	-0.52	0.56	0.55	-0.52	0.07	0.58	0.53	0.35	-0.54	-0.53	0.31	0.23	-0.46	0.05	0.12	-0.58	0.16		0.64	0.29
Property Plant And Equipment Net	0.44	0.31	0.77	0.69	0.79	-0.72	-0.77	0.89	0.82	-0.45	0.5	0.84	0.85	0.76	-0.61	-0.71	0.82	0.74	-0.26	0.66	0.63	-0.92	0.67	0.64		0.16
Net Receivables	-0.24	0.71	0.49	-0.29	0.6	0.24	-0.69	0.19	0.61	0.01	-0.16	0.58	0.42	0.18	-0.26	-0.33	-0.29	-0.38	0.24	-0.45	-0.5	-0.41	-0.45	0.29	0.16

Click cells to compare fundamentals

Mustang Bio Account Relationship Matchups

Mustang Bio fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Other Current Liab	236K	3.8M	9.2M	(270K)	8.3M	8.7M
Total Current Liabilities	7.8M	9.5M	10.8M	15.1M	15.4M	9.2M
Total Stockholder Equity	51.7M	98.4M	112.4M	46.3M	123K	116.9K
Net Tangible Assets	36.4M	51.7M	98.4M	112.4M	129.3M	135.7M
Net Debt	(45.9M)	(95.6M)	(107.6M)	(44.3M)	(3.7M)	(3.9M)
Retained Earnings	(125.5M)	(185.5M)	(251.8M)	(329.4M)	(381.0M)	(361.9M)
Accounts Payable	2.5M	9.2M	10.5M	14.5M	6.3M	6.5M
Common Stock Shares Outstanding	2.4M	3.5M	5.9M	6.9M	8.6M	5.3M
Non Current Liabilities Total	14.0M	2.0M	2.0M	31.0M	2.2M	2.1M
Capital Surpluse	98.7M	113.4M	172.2M	276.0M	317.4M	333.2M
Other Stockholder Equity	172.2M	276.0M	359.9M	374.5M	380.5M	223.5M
Total Liab	21.8M	11.5M	12.8M	46.1M	17.6M	15.5M
Total Assets	73.4M	109.9M	125.2M	92.4M	17.7M	16.9M
Cash	61.4M	97.8M	109.6M	75.7M	6.2M	5.9M
Non Current Assets Total	10.4M	10.4M	13.5M	13.6M	6.4M	8.8M
Other Assets	771K	1.3M	2.8M	1.4M	1.6M	1.3M
Cash And Short Term Investments	61.4M	97.8M	109.6M	75.7M	6.2M	5.9M
Retained Earnings Total Equity	(48.4M)	(79.1M)	(125.5M)	(185.5M)	(166.9M)	(158.6M)
Liabilities And Stockholders Equity	73.4M	109.9M	125.2M	92.4M	17.7M	16.9M
Total Current Assets	63.1M	99.5M	111.7M	78.9M	11.3M	10.8M
Accumulated Other Comprehensive Income	4.9M	7.9M	4.3M	1.1M	591K	561.5K
Property Plant Equipment	9.1M	9.1M	12.1M	12.3M	14.2M	8.0M
Property Plant And Equipment Net	9.1M	9.1M	12.1M	12.3M	4.8M	8.8M
Net Receivables	19K	15K	50K	36K	3.9M	4.1M
Other Current Assets	1.6M	1.7M	2.0M	3.2M	1.2M	1.7M
Net Invested Capital	65.1M	98.4M	112.4M	73.7M	123K	116.9K
Property Plant And Equipment Gross	9.1M	9.1M	12.1M	12.3M	9.3M	9.5M
Net Working Capital	55.3M	90.0M	100.9M	63.7M	(4.0M)	(3.8M)
Capital Stock	4K	7K	9K	11K	1K	950.0

Pair Trading with Mustang Bio

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mustang Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mustang Bio will appreciate offsetting losses from the drop in the long position's value.

Moving together with Mustang Stock

0.9	VALN	Valneva SE ADR	Pair Corr
0.86	ERNA	Eterna Therapeutics	Pair Corr

Moving against Mustang Stock

0.88	GILD	Gilead Sciences	Pair Corr
0.72	FLGC	Flora Growth Corp	Pair Corr
0.71	EWTX	Edgewise Therapeutics	Pair Corr
0.65	BMY	Bristol Myers Squibb Aggressive Push	Pair Corr
0.45	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr

The ability to find closely correlated positions to Mustang Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mustang Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mustang Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mustang Bio to buy it.

The correlation of Mustang Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mustang Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mustang Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Mustang Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Mustang Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mustang Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mustang Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mustang Bio Stock:

How To Invest In Mustang

Details

Is Mustang Stock a good investment?

Details

What is Mustang Bio's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mustang Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Mustang Stock, please use our How to Invest in Mustang Bio guide.

You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mustang Bio. If investors know Mustang will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mustang Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.72)

Revenue Per Share

(0)

Return On Assets

(1.05)

Return On Equity

(11.91)

The market value of Mustang Bio is measured differently than its book value, which is the value of Mustang that is recorded on the company's balance sheet. Investors also form their own opinion of Mustang Bio's value that differs from its market value or its book value, called intrinsic value, which is Mustang Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mustang Bio's market value can be influenced by many factors that don't directly affect Mustang Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Mustang Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mustang Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mustang Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Mustang Operating Income vs Reconciled Depreciation Analysis

Operating Income vs Reconciled Depreciation

Operating Income vs Reconciled Depreciation Correlation Analysis

Correlation Coefficient

Operating Income

Reconciled Depreciation

Mustang Bio fundamental ratios Correlations

Mustang Bio Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Mustang Bio fundamental ratios Accounts

Pair Trading with Mustang Bio

Moving together with Mustang Stock

Moving against Mustang Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Capital Surpluse	+ 1.0	Common Stock Total Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock Total Equity	+ 0.99	Net Tangible Assets
Capital Surpluse	+ 0.99	Net Tangible Assets
Cash And Short Term Investments	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets

Net Debt	- 0.98	Total Stockholder Equity
Retained Earnings Total Equity	- 0.97	Other Stockholder Equity
Retained Earnings Total Equity	- 0.97	Capital Surpluse
Common Stock Total Equity	- 0.97	Retained Earnings
Retained Earnings Total Equity	- 0.96	Common Stock Total Equity
Capital Surpluse	- 0.96	Retained Earnings